MT103 family of therapeutic compounds
Treatment for Non-small Cell Lung Cancer
Updated: August 1, 2007
 

Product Family

The MT103 family of therapeutic compounds was screened from tens of thousand of designed candidates with an optimal activity profile against non-small cell lung cancer, using Medisyn’s Forward Engineering™ in silico techniques.  MT103 predictions for activity and specificity have been validated in vitro with the National Cancer Institute (NCI) 3-cell and 60-cell line testing. In addition to identifying active chemical analogs, Medisyn has designed “property analogs” as backup lead candidates – these are chemically diverse structures possessing the same therapeutic properties as MT103. Drug-like MT103 and its analogs show remarkable promise and potential as candidates for pre-clinical and clinical evaluation. 

At-a-glance